Critical Review: Cybin (CYBN) and Its Competitors

Cybin (NYSE:CYBN) is one of 436 public companies in the “Biotechnology” industry, but how does it contrast to its rivals? We will compare Cybin to related businesses based on the strength of its valuation, institutional ownership, analyst recommendations, earnings, profitability, risk and dividends.

Risk and Volatility

Cybin has a beta of 0.42, indicating that its stock price is 58% less volatile than the S&P 500. Comparatively, Cybin’s rivals have a beta of 1.27, indicating that their average stock price is 27% more volatile than the S&P 500.

Institutional & Insider Ownership

17.9% of Cybin shares are owned by institutional investors. Comparatively, 28.8% of shares of all “Biotechnology” companies are owned by institutional investors. 15.0% of Cybin shares are owned by company insiders. Comparatively, 26.1% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings and price targets for Cybin and its rivals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cybin	0	0	3	0	3.00
Cybin Competitors	728	2171	5054	56	2.55

Cybin presently has a consensus price target of $50.50, indicating a potential upside of 426.04%. As a group, “Biotechnology” companies have a potential upside of 19.11%. Given Cybin’s stronger consensus rating and higher probable upside, analysts clearly believe Cybin is more favorable than its rivals.

Profitability

This table compares Cybin and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cybin	N/A	-109.05%	-97.85%
Cybin Competitors	-8,545.13%	-107.15%	-22.83%

Earnings and Valuation

This table compares Cybin and its rivals top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Cybin	N/A	-$35.93 million	-48.00
Cybin Competitors	$148.99 million	-$13.00 million	-138.76

Cybin’s rivals have higher revenue and earnings than Cybin. Cybin is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Summary

Cybin rivals beat Cybin on 8 of the 13 factors compared.

Cybin Company Profile

Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company’s development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 1/2a clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds. The company has research and collaboration agreement with TMS Neurohealth Centers Inc. for development of psychedelic compound-based therapeutics; Kernel for use of Kernel flow technology to measure neural activity; and Greenbook TMS to establish mental health centers. The company is headquartered in Toronto, Canada.